How Stable Ischemic Heart Disease Leads to Acute Coronary Syndrome in COVID-19?

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, the increased mortality risk of patients with underlying cardiovascular diseases and COVID-19 was raised. Besides, coronavirus itself enhances the incidence of myocardial injury, which suggests a two-sided relation. We aimed to discuss the role of COVID-19 in the progression of stable coronary artery disease (CAD) to acute coronary syndrome (ACS), which might lead to a greater rate of out-of-hospital cardiac arrest and a higher fatality rate of ACS during the pandemic. We briefly reviewed several mechanisms in this regard: Systemic inflammation and cytokine release in critical patients; Plaque rupture and coronary thrombosis; Dysregulation of cytotoxic T-cell lymphocytes; Malignant ventricular arrhythmias. We reinforce applying more attention to COVID-19 patients with stable CAD during follow-up to prevent progression to ACS. These individuals should seriously observe World Health Organization protocols to avoid virus transmission by carriers. (www.actabiomedica.it)

[1]  L. Vetrugno,et al.  COVID-19 pandemic in an Italian obstetric Department: sharing our experience , 2021, Acta bio-medica : Atenei Parmensis.

[2]  D. Watkins.  Cardiovascular health and COVID-19: time to reinvent our systems and rethink our research priorities , 2020, Heart.

[3]  A. Gasbarrini,et al.  Angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID‐19 , 2020, Internal medicine journal.

[4]  Youssef S. Abdelwahed,et al.  Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translational OPTICO-ACS study. , 2020, European heart journal.

[5]  P. Libby,et al.  COVID-19 is, in the end, an endothelial disease , 2020, European heart journal.

[6]  D. Lewis,et al.  COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives , 2020, Nature Reviews Cardiology.

[7]  H. Tan.  How does COVID-19 kill at home and what should we do about it? , 2020, European heart journal.

[8]  G. Iotti,et al.  COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests , 2020, European heart journal.

[9]  Alon Yarkoni,et al.  Decrease in acute coronary syndrome presentations during the COVID-19 pandemic in upstate New York , 2020, American Heart Journal.

[10]  R. de Caterina,et al.  Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era , 2020, European heart journal.

[11]  V. Chinchilli,et al.  The association of cardiovascular disease and other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis , 2020, medRxiv.

[12]  Catherine Klersy,et al.  Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy , 2020, The New England journal of medicine.

[13]  F. Fedele,et al.  Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy , 2020, The New England journal of medicine.

[14]  M. Ramakers,et al.  High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[15]  G. Fonarow,et al.  Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. , 2020, JAMA cardiology.

[16]  Manish Bansal,et al.  Cardiovascular disease and COVID-19 , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[17]  P. Libby,et al.  Reassessing the Mechanisms of Acute Coronary Syndromes: The “Vulnerable Plaque” and Superficial Erosion , 2019, Circulation research.

[18]  T. Chao,et al.  Increased risk of ventricular tachycardia and cardiovascular death in patients with myocarditis during the long-term follow-up , 2017, Medicine.

[19]  Milan Sonka,et al.  Regions of low endothelial shear stress are the sites where coronary plaque progresses and vascular remodelling occurs in humans: an in vivo serial study. , 2007, European heart journal.

[20]  R. Furchgott.  Endothelium-Derived Relaxing Factor: Discovery, Early Studies, and Identifcation as Nitric Oxide (Nobel Lecture). , 1999, Angewandte Chemie.

[21]  P. Libby,et al.  Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells , 1987, The Journal of experimental medicine.